Information Provided By:
Fly News Breaks for January 15, 2019
AIMT
Jan 15, 2019 | 05:07 EDT
Piper Jaffray analyst Christopher Raymond says the FDA review delay for Aimmune Therapeutics' AR101 due to the government shutdown does not change bullish thesis on the shares. In a research note titled "Trump Shutdown Claims its First Biotech Victim (That We Know Of)," Raymond, while admitting that there is clearly no end in sight to the current shutdown, urges investor patience with respect to Aimmune shares as the "fundamental story has not changed." He keeps an Overweight rating on the shares with a $60 price target.
News For AIMT From the Last 2 Days
There are no results for your query AIMT